ZFIN ID: ZDB-FISH-150901-19364
Fish name: mef2cab1086/b1086
Genotype: mef2cab1086/b1086
Targeting Reagent: none
HUMAN DISEASE MODELED by mef2cab1086/b1086
No data available
GENE EXPRESSION
Gene expression in mef2cab1086/b1086
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab2-mef2 standard conditions Fig. S2 with image from Hinits et al., 2012
Reporter gene expression No data available
PHENOTYPE
Phenotype in mef2cab1086/b1086
Phenotype Conditions Figures
cardiac muscle cell undifferentiated, abnormal standard conditions Fig. 2 with image from Hinits et al., 2012
cardiac muscle cell differentiation arrested, abnormal standard conditions Fig. 2 with image from Hinits et al., 2012
ceratohyal cartilage morphology, abnormal control Fig 2 with imageFig 7 with imageFig 8 with imageFig 9 with imageFig 11 with image from Sucharov et al., 2019
ceratohyal cartilage morphology, ameliorated chemical treatment: dibenzoazepine Fig 8 with image from Sucharov et al., 2019
ceratohyal-interhyal joint fused with ceratohyal-interhyal joint, abnormal control Fig 2 with imageFig 7 with imageFig 8 with imageFig 9 with imageFig 11 with image from Sucharov et al., 2019
ceratohyal-interhyal joint fused with ceratohyal-interhyal joint, ameliorated chemical treatment: dibenzoazepine Fig 8 with image from Sucharov et al., 2019
head mef2ca expression decreased amount, abnormal standard conditions Fig 5 with image from Sucharov et al., 2019
head dlx5a expression decreased amount, abnormal standard conditions Fig 6 with image from Sucharov et al., 2019
head hey1 expression increased amount, abnormal standard conditions Fig 10 with image from Sucharov et al., 2019
head mef2aa expression increased amount, abnormal standard conditions Fig 5 with image from Sucharov et al., 2019
head jag1b expression increased amount, abnormal standard conditions Fig 10 with image from Sucharov et al., 2019
head mef2d expression increased amount, abnormal standard conditions Fig 5 with image from Sucharov et al., 2019
head her6 expression increased amount, abnormal standard conditions Fig 10 with image from Sucharov et al., 2019
hyohyoideus inverted, abnormal standard conditions Fig 3 with image from Sucharov et al., 2019
interhyoideus structure, abnormal standard conditions Fig 3 with image from Sucharov et al., 2019
intermandibularis structure, abnormal standard conditions Fig 3 with image from Sucharov et al., 2019
Meckel's cartilage decreased size, abnormal chemical treatment: dibenzoazepine Fig 8 with image from Sucharov et al., 2019
Meckel's cartilage decreased size, abnormal control Fig 2 with imageFig 7 with imageFig 8 with imageFig 9 with imageFig 11 with image from Sucharov et al., 2019
opercle mislocalised, abnormal control Fig 2 with imageFig 5 with imageFig 7 with imageFig 8 with imageFig 9 with imageFig 11 with image from Sucharov et al., 2019
opercle mislocalised, ameliorated chemical treatment: dibenzoazepine Fig 8 with image from Sucharov et al., 2019
pharyngeal arch 2 her6 expression increased distribution, abnormal standard conditions Fig 10 with image from Sucharov et al., 2019
quadrate-anguloarticular joint fused with quadrate-anguloarticular joint, abnormal control Fig 2 with imageFig 7 with imageFig 8 with imageFig 9 with imageFig 11 with image from Sucharov et al., 2019
quadrate-anguloarticular joint fused with quadrate-anguloarticular joint, abnormal chemical treatment: dibenzoazepine Fig 8 with image from Sucharov et al., 2019
symplectic decreased size, abnormal chemical treatment: dibenzoazepine Fig 8 with image from Sucharov et al., 2019
symplectic decreased size, abnormal control Fig 2 with imageFig 4 with imageFig 7 with imageFig 8 with imageFig 9 with imageFig 11 with image from Sucharov et al., 2019

CITATIONS  (5)